Grove Biopharma

Grove Biopharma is developing a new class of biotherapeutics to address chronic inflammatory and neurodegenerative diseases. Its proprietary Protein-Like Polymers™ (PLPs) are synthetic, cell-penetrant biologics designed to engage well-validated but “undruggable” intracellular targets. By leveraging precision polymer science, protein engineering, and medicinal chemistry, Grove Biopharma aims to unlock new treatment possibilities for diseases with significant unmet medical needs.